Return to Home

Anavex Life Sciences Corp.

AVXL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Anavex Life Sciences Corp. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company’s claim noting “there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct ‘complexifiers’.” Additionally, a biotech journalist commented on AVXL’s findings stating “[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.”

Following this news, AVXL’s stock price fell by $2.47 per share, or approximately 20% to close at $9.58.

Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.”

Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Find More Cases

Ticker Symbol Company Name Join Deadline
VNET VNET Group, Inc. February 26, 2024 Join
ASRT Assertio Holdings, Inc. March 05, 2024 Join
DADA Dada Nexus Limited March 11, 2024 Join
BNTX BioNTech SE March 12, 2024 Join
MBLY Mobileye Global Inc. March 18, 2024 Join
BIVI BioVie Inc. March 19, 2024 Join
ALVR AlloVir, Inc. March 19, 2024 Join
BTI British American Tobacco p.l.c. March 25, 2024 Join
EVVTY Evolution AB (publ) March 25, 2024 Join
ADM Archer-Daniels-Midland Company March 25, 2024 Join
RILY B. Riley Financial, Inc. March 25, 2024 Join
CART Maplebear Inc. d/b/a Instacart March 25, 2024 Join
EAF GrafTech International Ltd. March 25, 2024 Join
SAVA Cassava Sciences, Inc. April 02, 2024 Join
IRTC iRhythm Technologies, Inc. April 08, 2024 Join
NYCB New York Community Bancorp, Inc. April 08, 2024 Join
HUT Hut 8 Corp. April 08, 2024 Join
XPOF Xponential Fitness, Inc. April 09, 2024 Join
AMLX Amylyx Pharmaceuticals, Inc. April 09, 2024 Join
INMD InMode Ltd. April 15, 2024 Join
AMPL Amplitude, Inc. April 15, 2024 Join
NOVA Sunnova Energy International Inc. April 16, 2024 Join
INOD Innodata Inc. April 22, 2024 Join
DKS DICK's Sporting Goods, Inc. April 22, 2024 Join